Open Payments

JEANNE D PERELES-ORTIZ

Type
Physician · Allopathic & Osteopathic Physicians / Family Medicine
Where
COLSTRIP, MT
NPI
1932174950
Received
$8,719 in 11 records, 2019 to 2021 ($7,024 general, $1,695 research)
As principal investigator
$70,814 of research payments to others in 26 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment2$2,890
2021Research payment1$858
2020General payment5$4,079
2020Research payment1$836
2019General payment2$54

By company

CompanyRecordsAmountYears
Novo Nordisk Inc8$7,0022019–2021
Eli Lilly and Company2$1,6952020–2021
Boehringer Ingelheim Pharmaceuticals, Inc.1$222019

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v5$6,936
Research payment2$1,695
Food and Beverage3$56
Education1$32

Records

DateCompanyAmountNatureFormProductStudyYear
2021-09-30Novo Nordisk Inc$867Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBELSUS Drug, Diabetes2021
2021-04-12Eli Lilly and Company$858Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2021
2021-02-15Novo Nordisk Inc$2,023Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBELSUS Drug, Diabetes2021
2020-10-05Novo Nordisk Inc$289Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRYBELSUS Drug, Diabetes2020
2020-05-20Eli Lilly and Company$836Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2020
2020-05-01Novo Nordisk Inc$3,179Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOzempic Drug, Diabetes2020
2020-05-01Novo Nordisk Inc$578Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOzempic Drug, Diabetes2020
2020-02-28Novo Nordisk Inc$19Food and BeverageIn-kind items and servicesTresiba Drug, Diabetes2020
2020-01-09Novo Nordisk Inc$14Food and BeverageIn-kind items and servicesTresiba Drug, Diabetes2020
2019-05-15Boehringer Ingelheim Pharmaceuticals, Inc.$22Food and BeverageIn-kind items and services2019
2019-04-01Novo Nordisk Inc$32EducationIn-kind items and servicesVictoza Drug, Diabetes2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2020-09-08SANOFI US SERVICES INC.Billings Clinic$3,606A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2020
2020-06-15SANOFI US SERVICES INC.Billings Clinic$3,056A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2020
2020-05-18SANOFI US SERVICES INC.Billings Clinic$1,756A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2020
2020-03-03SANOFI US SERVICES INC.Billings Clinic$3,512A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2020
2020-02-10SANOFI US SERVICES INC.Billings Clinic$3,137A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2020
2019-12-19Novo Nordisk ASBILLINGS CLINIC$4,541NN9924-42572019
2019-12-11SANOFI US SERVICES INC.BILLINGS CLINIC$1,756A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-11-25SANOFI US SERVICES INC.BILLINGS CLINIC$750A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-11-04SANOFI US SERVICES INC.BILLINGS CLINIC$2,575A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-09-23SANOFI US SERVICES INC.BILLINGS CLINIC$1,142A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-08-12SANOFI US SERVICES INC.BILLINGS CLINIC$1,100A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-07-02SANOFI US SERVICES INC.BILLINGS CLINIC$375A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-06-10SANOFI US SERVICES INC.BILLINGS CLINIC$2,200A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-04-30Novo Nordisk ASBILLINGS CLINIC$72NN9924-42572019
2019-03-29Novo Nordisk ASBILLINGS CLINIC$72NN9924-42572019
2019-03-26Novo Nordisk ASBILLINGS CLINIC$1,000NN9068-42282019
2019-03-26Novo Nordisk ASBILLINGS CLINIC$20,557NN9068-42282019
2019-02-28Novo Nordisk ASBILLINGS CLINIC$72NN9924-42572019
2019-02-21Novo Nordisk ASBILLINGS CLINIC$465NN9924-42572019
2019-01-31Novo Nordisk ASBILLINGS CLINIC$72NN9924-42572019
2019-01-28SANOFI US SERVICES INC.BILLINGS CLINIC$8,591A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-01-28SANOFI US SERVICES INC.BILLINGS CLINIC$550A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-01-28SANOFI US SERVICES INC.BILLINGS CLINIC$227A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-01-28SANOFI US SERVICES INC.BILLINGS CLINIC$3,426A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019
2019-01-24Novo Nordisk ASBILLINGS CLINIC$899NN9924-42572019
2019-01-21SANOFI US SERVICES INC.BILLINGS CLINIC$5,300A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Rosebud CountyColstrip city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Colstrip, MT, county Rosebud County, MT, state Montana; placed by its city name.

MeasurePlace (city or town)
Colstrip, MT
County
Rosebud County, MT
State
Montana
Population B010032,1018,1651,116,875
Population, 2020 census P12,0968,3291,084,225
Median age B0100244.238.040.4
Under 18 B0100127.2%28.3%21.0%
65 and over B0100113.5%17.6%20.1%
Households B110018023,070458,859
Foreign born B050020.6%2.3%2.3%
Median household income B19013$82,500$49,914$72,509
Median family income B19113$120,313$69,853$92,794
Per capita income B19301$42,447$29,231$41,711
Poverty rate B170019.4%24.5%11.5%
Unemployment rate B230258.2%10.6%3.6%
Civilian labor force B230251,0893,568568,568
Mean commute (minutes) B0801310.715.519.1
Bachelor's degree or higher B1500325.9%20.9%35.2%
Housing units B250019403,779528,419
Owner-occupied B2500382.8%63.6%69.2%
Renters B2500317.2%36.4%30.8%
Median home value B25077$194,900$182,400$375,800
Median gross rent B25064$659$672$1,081
White, not Hispanic B0300267.7%51.4%83.6%
Black B030020.0%0.1%0.4%
Hispanic or Latino B030027.2%3.7%4.6%
Asian B030020.0%2.0%0.8%
American Indian and Alaska Native B0300222.3%36.8%5.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Colstrip, MT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.